Theremia reduces side effects and increases medication efficacy for various patient groups.
Theremia has raised $3.2M in total funding. The most recent round was Seed. The last funding was announced in November 2024.
Theremia's investors include Bpifrance, Entrepreneurs First, Salica, Eurazeo, Better Angle.
Theremia is headquartered in Paris, France.
Theremia reduces side effects and increases medication efficacy for various patient groups.
Theremia is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Theremia — Funding & Investors." VCBacked, November 7, 2024, https://www.vcbacked.co/company/theremia. Accessed July 20, 2026.
VCBacked. (2024). Theremia — Funding & Investors. Retrieved July 20, 2026, from https://www.vcbacked.co/company/theremia
{{cite web |title=Theremia — Funding & Investors |url=https://www.vcbacked.co/company/theremia |website=VCBacked |access-date=July 20, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated